Načítá se...
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase
PURPOSE: Gemcitabine (GEM) is currently the standard first line treatment for pancreatic cancer; however, the overall survival of patients with this disease remains poor. Imexon is a pro-oxidant small molecule which produced a high response rate in combination with GEM in a phase I trial in pancreat...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2987536/ https://ncbi.nlm.nih.gov/pubmed/20339847 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1306-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|